<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Drug ther</journal-id><journal-id journal-id-type="iso-abbrev">Curr Drug ther</journal-id><journal-id journal-id-type="publisher-id">CDTH</journal-id><journal-title-group><journal-title>Current Drug Therapy</journal-title></journal-title-group><issn pub-type="ppub">1574-8855</issn><issn pub-type="epub">2212-3903</issn><publisher><publisher-name>Bentham Science Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22876216</article-id><article-id pub-id-type="pmc">3412202</article-id><article-id pub-id-type="publisher-id">CDTH-6-296</article-id><article-id pub-id-type="doi">10.2174/157488511798109592</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Duloxetine in Patients with Chronic Pain Conditions</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Skljarevski</surname><given-names>Vladimir</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Shuyu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Iyengar</surname><given-names>Smriti</given-names></name></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Souza</surname><given-names>Deborah</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alaka</surname><given-names>Karla</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chappell</surname><given-names>Amy</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wernicke</surname><given-names>Joachim</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff>Lilly Research Laboratories, Indianapolis, IN 46285, USA</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Eli Lilly and Company, Lilly
Corporate Center, Indianapolis, IN 46285, USA; Tel: 317-433-5793;
Fax: 317-276-6026; E-mail: <email xlink:href="jfwernicke@lilly.com">jfwernicke@lilly.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2011</year></pub-date><pub-date pub-type="epub"><month>11</month><year>2011</year></pub-date><volume>6</volume><issue>4</issue><fpage>296</fpage><lpage>303</lpage><history><date date-type="received"><day>20</day><month>5</month><year>2011</year></date><date date-type="rev-recd"><day>12</day><month>9</month><year>2011</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9;2011 Bentham Science Publishers</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The primary objective of this study is to review the efficacy of duloxetine in treating chronic pain using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations for clinical significance across chronic pain states. These include pain intensity, patient ratings of overall improvement, physical functioning, and mental functioning. This review comprised the side-by-side analyses of 12 double-blind, placebo-controlled trials of duloxetine in patients with chronic pain (diabetic peripheral neuropathic pain, fibromyalgia, chronic pain due to osteoarthritis, and chronic low back pain). Patients received duloxetine (60 to 120 mg/day) or placebo. Average pain reduction was assessed over 3 months as the primary efficacy outcome. Other measures used were physical function and Patient Global Impression of Improvement. In 10 of the 12 studies, statistically significant greater pain reduction was observed for duloxetine- compared with placebo-treated patients. The response rates based on average pain reduction, improvement of physical function, and global impression were comparable across all 4 chronic pain states. Compared with patients on placebo, significantly more patients treated with duloxetine reported a moderately important pain reduction (&#x02265;30% reduction) in 9 of the 12 studies, a minimally important improvement in physical function in 8 of the 12 studies, and a moderately important to substantial improvement in Patient Global Impression of Improvement rating in 11 of the 12 studies. The analyses reported here show that duloxetine is efficacious in treating chronic pain as demonstrated by significant improvement in pain intensity, physical functioning, and patient ratings of overall improvement.</p></abstract><kwd-group><title>Keywords</title><kwd>Chronic low back pain</kwd><kwd>chronic pain</kwd><kwd>diabetic peripheral neuropathic pain</kwd><kwd>duloxetine</kwd><kwd>efficacy</kwd><kwd>fibromyalgia</kwd><kwd>osteoarthritis.</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>The prevalence of chronic pain in the United States and Europe has been estimated at 35.5% [<xref ref-type="bibr" rid="R1">1</xref>] and 19% (of adults with moderate to severe intensity) [<xref ref-type="bibr" rid="R2">2</xref>], respectively. Depending on how it is defined, chronic pain is estimated to have a worldwide prevalence of 11% to 55% [<xref ref-type="bibr" rid="R3">3</xref>]. Pain represents the most common reason for patients to seek medical counsel [<xref ref-type="bibr" rid="R4">4</xref>]. Many types of pain, including chronic pain, affecting different patient populations (elderly, children, minorities, substance abusers) remain undertreated [<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref>], and a complete resolution of pain is rarely achieved [<xref ref-type="bibr" rid="R7">7</xref>]. Untreated or undertreated pain has significant physical, psychological, social, and financial consequences [<xref ref-type="bibr" rid="R8">8</xref>].</p><p>Unlike acute (nociceptive) pain, chronic pain is a pathological state associated with functional and structural changes within the peripheral and central nervous systems. Among these changes, central sensitization and impairment of associated pain inhibitory circuits have been extensively researched [<xref ref-type="bibr" rid="R9">9</xref>-<xref ref-type="bibr" rid="R12">12</xref>]. These pathophysiological mechanisms are involved in and at least partially responsible for the development and maintenance of chronic pain states, regardless of their respective underlying etiologies (e.g., neuropathy, inflammation, or tissue damage).</p><p>Three main categories of chronic pain are typically recognized [<xref ref-type="bibr" rid="R13">13</xref>]. These include neuropathic pain (resulting from nerve damage or dysfunction either in the peripheral or in the central nervous system, e.g., diabetic peripheral neuropathic pain [DPNP]), inflammatory/joint-related pain (resulting from peripheral inflammation or peripheral tissue/joint damage, e.g., early-stage osteoarthritis), and noninflammatory/non-neuropathic pain (also called functional pain by some pain researchers) which results from centrally impaired pain processing like in fibromyalgia (FM). Chronic pain conditions such as chronic low back pain (CLBP) may result from a number of causes, which can technically fall into any of these 3 chronic pain categories just discussed.</p><p>Serotonin (5-HT) and norepinephrine (NE) have been implicated in the mediation of endogenous pain inhibitory mechanisms <italic>via </italic>the descending pain inhibitory pathways in the brain and spinal cord [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R14"> 14</xref>,<xref ref-type="bibr" rid="R15"> 15</xref>]. In chronic pain states, the net inhibitory effect of these monoamines is postulated to be reduced or lost; consequently, shifting the descending pain modulatory system from a state of inhibition towards a state of pain facilitation [<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17"> 17</xref>]. Duloxetine is a potent and selective inhibitor of 5-HT and NE reuptake <italic>in vitro</italic> and <italic>in vivo</italic> in the central nervous system (CNS) [<xref ref-type="bibr" rid="R18">18</xref>]. Preclinical studies have shown that duloxetine effectively reduces pain behavior across a range of persistent, neuropathic, and inflammatory pain models [<xref ref-type="bibr" rid="R19">19</xref>-<xref ref-type="bibr" rid="R21">21</xref>], in a dose range that is consistent with inhibition of 5-HT and NE reuptake. Thus, the analgesic effect of duloxetine is believed to result from increased activity of 5-HT and NE within the CNS [<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R20"> 20</xref>,<xref ref-type="bibr" rid="R21"> 21</xref>], presumably either by enhancing descending pain inhibitory pathways in the brain and spinal cord or other unknown CNS actions. </p><p>Irrespective of the underlying pathology or its absence, pain sensation becomes maladaptive, pathological, and enhanced, at least partly, due to the imbalance between excitatory and inhibitory pathways within the CNS. This supports the hypothesis that a centrally active agent impacting the pain processing/sensing pathways may have an analgesic effect across chronic pain conditions. In view of this, duloxetine has been evaluated in DPNP, FM, chronic pain due to osteoarthritis (OA), and CLBP. </p><p>In previously published clinical trials, duloxetine has been shown to be effective in treating patients with DPNP [<xref ref-type="bibr" rid="R22">22</xref>-<xref ref-type="bibr" rid="R24">24</xref>] and FM [<xref ref-type="bibr" rid="R25">25</xref>-<xref ref-type="bibr" rid="R28">28</xref>]. Data from placebo-controlled trials have also provided evidence of duloxetine&#x02019;s efficacy in OA pain [<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R30"> 30</xref>] as well as CLBP [<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32"> 32</xref>].</p><p>While prior studies established the superiority of duloxetine relative to placebo in DPNP, FM, OA, and CLBP, the analyses presented here address the clinical significance of those findings. In order to accomplish that, we used the criteria of clinical significance in chronic pain trials as proposed by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) [<xref ref-type="bibr" rid="R33">33</xref>]. These include pain intensity, physical functioning, and patients&#x02019; ratings of overall improvement.</p><p>Safety and tolerability of duloxetine has been described previously (and will not be addressed here) in the individual publications cited above, and articles with a focus on safety [<xref ref-type="bibr" rid="R34">34</xref>-<xref ref-type="bibr" rid="R42">42</xref>].</p></sec><sec sec-type="methods"><title>METHODS</title><p>This report is based on the side-by-side analyses of 12 double-blind, placebo-controlled, randomized, multicenter clinical trials of duloxetine in patients with chronic pain (OA: study HMFG [<xref ref-type="bibr" rid="R29">29</xref>], study HMEP [<xref ref-type="bibr" rid="R30">30</xref>]; CLBP: study HMEN [<xref ref-type="bibr" rid="R43">43</xref>], study HMEO [<xref ref-type="bibr" rid="R31">31</xref>], study HMGC [<xref ref-type="bibr" rid="R32">32</xref>]; DPNP: study HMAW [<xref ref-type="bibr" rid="R22">22</xref>], study HMAVb [<xref ref-type="bibr" rid="R23">23</xref>], study HMAVa [<xref ref-type="bibr" rid="R24">24</xref>]; FM: study HMBO [<xref ref-type="bibr" rid="R25">25</xref>], study HMCA [<xref ref-type="bibr" rid="R26">26</xref>], study HMCJ [<xref ref-type="bibr" rid="R27">27</xref>], study HMEF [<xref ref-type="bibr" rid="R28">28</xref>]). The trials were of at least 12-week duration and evaluated duloxetine doses of 60-mg to 120-mg daily. Several of the studies in FM were of 6-month duration, but for comparison purposes only 3-month data are presented here.</p><p>Details about the inclusion and exclusion criteria for each of the chronic pain states are provided in the published manuscripts for the individual studies [<xref ref-type="bibr" rid="R22">22</xref>-<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R30"> 30</xref>,<xref ref-type="bibr" rid="R32"> 32</xref>,<xref ref-type="bibr" rid="R43"> 43</xref>]. All of the studies required that patients have a 24-hour average pain rating of 4 or greater based on an 11-point numerical rating scale at study entry and have chronic pain for at least 3 to 6 months prior to study entry. In the OA and FM studies, patients had to meet the criteria for OA of the knee or FM as defined by the American College of Rheumatology. In the CLBP studies, patients included were those with non-neuropathic pain (Class 1 and 2 per the Quebec Classification of Spinal Disorders).</p><p>Patients were excluded if they had any serious medical or psychiatric condition that could compromise their participation in the study. All protocols excluded patients with clinically significant impairment in mental function. Patients with major depressive disorder were excluded from all studies except those in FM.</p><p>The primary efficacy measure in all studies was the 24-hour average pain rating (rating scale ranging from 0 [no pain] to 10 [worst possible pain]). Outcome measures used to assess physical functioning included the Brief Pain Inventory (BPI) average physical interference (used in the DPNP and FM studies, the average of 3 physical interference items, namely: general activity, walking ability, and normal work; physical function response was defined as 1 point decrease on the average of the 3 physical interference items [general activity, walking ability, and normal work]), the Western Ontario and McMaster Universities (WOMAC) [<xref ref-type="bibr" rid="R44">44</xref>] physical function subscale (in the OA studies), and the Roland Morris Disability Questionnaire (RMDQ-24) [<xref ref-type="bibr" rid="R45">45</xref>] (in the CLBP studies). The Patient Global Impression of Improvement (PGI-I) scale measured patients&#x02019; ratings of overall improvement compared to study baseline (range from 0 [very much better] to 7 [very much worse]).</p><p>The benchmarks used to assess the clinical importance of changes in some of the above measures were based on the recommendations of the IMMPACT consensus on the clinical significance of change across pain states [<xref ref-type="bibr" rid="R33">33</xref>]. For measuring pain intensity, a decrease of &#x02265;30% and &#x02265;50% are considered &#x02018;moderately&#x02019; and &#x02018;substantially&#x02019; important, respectively [<xref ref-type="bibr" rid="R33">33</xref>]. One point decrease in BPI physical interference is considered clinically important. A change of &#x02018;much improved&#x02019; (PGI-I endpoint = 2) to &#x02018;very much improved&#x02019; (PGI-I endpoint = 1) are considered &#x02018;moderately&#x02019; to &#x02018;substantially&#x02019; important, respectively, on the Patient Global Impression of Change [<xref ref-type="bibr" rid="R33">33</xref>]. For the WOMAC scale, a score of &#x02264;31 is considered to be an acceptable physical symptom state [<xref ref-type="bibr" rid="R46">46</xref>], and for the RMDQ [<xref ref-type="bibr" rid="R47">47</xref>-<xref ref-type="bibr" rid="R49">49</xref>] a change of &#x02264;-3.5 is considered clinically meaningful.</p><sec><title>Statistical Methods</title><p>All analyses were conducted on an intent-to-treat (ITT) basis. Treatment effects were evaluated based on 2-sided tests with a significance level of 0.05. No adjustments were made for multiple comparisons. When an average score was computed from individual items, it was calculated from nonmissing values.</p><p>For all analyses, baseline refers to the last nonmissing observation at or before the random assignment visit and endpoint refers to the last nonmissing observation in the 3-month treatment phase [last observation carried forward (LOCF)].</p><p>For continuous variables, an analysis of covariance (ANCOVA) model was used including baseline value, treatment, and investigator. Type III sum-of-squares for the least-squares mean (LS Mean) was used to assess treatment difference. For the categorical variable, Fisher&#x02019;s exact test was used to assess the treatment difference. For time-to-first-response analysis, the Kaplan-Meier survival estimate was calculated by treatment group at each time point (Week 1 to Week 13). Patients who did not meet response criteria were considered as right-censored observation (a data point is above a certain value but it is unknown by how much). Treatment difference was assessed through log-rank test.</p><p>The term &#x02018;significant&#x02019; indicates statistical significance throughout the manuscript. SAS version 9 was used to perform all statistical analyses.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Among OA and CLBP patients, the majority were Caucasian (86.6%), female (63.4%), had a mean age of 56 years, and a mean duration of study drug exposure of 77.7 days. For DPNP patients, the majority were Caucasian (84.4%), male (56.8%), had a mean age of 60 years, and mean duration of study drug exposure of 77.6 days; whereas, in FM patients, the majority were Caucasian (87.5%), female (94.8%), had a mean age of 50 years, and a mean duration of study drug exposure of 110.2 days. In duloxetine-treated OA and CLBP patients, the most common (&#x02265;5%) adverse events were nausea (13.9%), dry mouth (7.0%), constipation (6.9%), insomnia (6.6%), diarrhea (5.7%), dizziness (5.7%), somnolence (5.6%), and fatigue (5.0%). The most common (&#x02265;5%) adverse events among duloxetine-treated DPNP patients, were nausea (23.9%), somnolence (15.9%), dizziness (11.0%), diarrhea (9.6%), insomnia (8.9%), fatigue (8.6%), constipation (9.4%), hyperhidrosis (8.5%), dry mouth (7.5%), and decreased appetite (5.3%). Among duloxetine-treated FM patients, the most common (&#x02265;5%) adverse events were nausea (29.3%), headache (20.0%), dry mouth (18.2%), insomnia (14.5%), fatigue (13.5%), constipation (14.5%), diarrhea (11.6%), dizziness (11.0%), somnolence (9.6%), hyperhidrosis (6.8%), and decreased appetite (6.5%).</p><p>Patients taking duloxetine 60 mg to 120 mg daily, on a group mean level, demonstrated significantly greater reduction in 24-hour average pain compared with placebo in 10 of the 12 chronic pain studies (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). In the 2 remaining studies, duloxetine was numerically better than placebo. The observed baseline pain severity across the studies was approximately 6. On average, duloxetine-treated patients reported pain reduction of -1.43 to -3.14, while the range for placebo-treated patients was -0.67 to -1.93.</p><p>On the level of individual patient response, duloxetine-treated patients reported a significantly higher response rate in 8 of the 12 chronic pain studies based on 30% response criteria and 7 of the 12 studies based on 50% response criteria (Table <bold><xref ref-type="table" rid="T2">2</xref></bold>). On average, the 30% and 50% response rate for duloxetine-treated patients ranged from 37% to 69% and 26% to 53%, respectively, while the range for placebo-treated patients was 27% to 49% and 15% to 35%, respectively.</p><p>Compared with patients on placebo, patients treated with duloxetine had a significantly greater response rate in physical function improvement in 8 of the 12 studies (Table <bold><xref ref-type="table" rid="T3">3</xref></bold>).</p><p>Compared with patients on placebo, patients treated with duloxetine had a significantly greater PGI-improvement response rate in 11 of the 12 studies (Table <bold><xref ref-type="table" rid="T4">4</xref></bold>).</p><p>The survival analysis of the time to first 30% average pain reduction across the 12 CP studies showed a significant separation as early as 1 to 2 weeks, except for 3 studies where significant separation was not achieved until Week 3. Furthermore, the distribution curves of time to response for all 12 studies showed significant separation between duloxetine and placebo during the 3-month treatment phase (P&#x0003c;0.01).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Duloxetine hydrochloride is a selective dual 5-HT and NE reuptake inhibitor with central analgesic properties. Preclinically, duloxetine is efficacious in models of persistent, inflammatory, and neuropathic pain [<xref ref-type="bibr" rid="R19">19</xref>-<xref ref-type="bibr" rid="R21">21</xref>], suggesting that it may be efficacious in the treatment of chronic pain conditions in which central sensitization is believed to be one of the underlying pathophysiological mechanisms [<xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R51"> 51</xref>]. Central sensitization is dependent upon the activation of a descending pain facilitatory pathway originating in the brainstem [<xref ref-type="bibr" rid="R52">52</xref>]. Duloxetine, by enhancing monoaminergic tone, may potentially reduce the consequences of central sensitization by shifting the descending pain modulatory pathway from a state of facilitation to a state of inhibition [<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17"> 17</xref>]. Consistent with the preclinical data, duloxetine, has demonstrated remarkable consistency of analgesic effect across all 3 main categories of chronic pain.</p><p>Duloxetine-treated patients demonstrated a significantly greater pain reduction compared with placebo-treated patients in 10 of the 12 studies and a numerically greater reduction in the remaining 2 studies.</p><p>Patients receiving duloxetine for the treatment of chronic pain states had significantly higher response rates corresponding to clinically moderate and substantially important improvement compared with patients receiving placebo.</p><p>A 30% reduction from baseline to endpoint was used as one measure of response. A previous report by Farrar <italic>et al</italic>. [<xref ref-type="bibr" rid="R53">53</xref>] estimated that a decrease in pain intensity of 30% was associated with the patient rating of &#x02018;much improved&#x02019; and decreases of &#x02265;50% are associated with the patient rating of &#x02018;very much improved&#x02019; [<xref ref-type="bibr" rid="R54">54</xref>]. A subsequent study [<xref ref-type="bibr" rid="R55">55</xref>] has also demonstrated that on a 0 to 10 numeric rating scale of pain intensity for patient-reported &#x02018;average&#x02019; and &#x02018;worst&#x02019; pain, a percentage change of 34% was best associated with a clinically important difference, namely the PGI-I category of &#x02018;much better&#x02019; or higher, and a 51% reduction in pain from baseline was associated with &#x02018;very much better&#x02019;.</p><p>Duloxetine-treated patients demonstrated significant improvement in physical functioning in 8 of the 12 studies. Patients receiving duloxetine showed significant physical-function improvement as assessed by the BPI-Interference, as well as disease-specific measures like WOMAC physical function subscale (OA), and RMDQ-24 (CLBP). Regardless of the measures used in these studies, patients with chronic pain had a significant improvement in overall physical functioning.</p><p>There was also a significant overall improvement in duloxetine-treated patients as demonstrated by the PGI-improvement rating (a measure of the degree of change at the time of assessment).</p><p>The time-to-response data demonstrated that there was a significant separation between duloxetine and placebo at 1 to 2 weeks for 9 of the 12 studies and at Day 21 for the remaining 3 studies.</p><p>The limitations to this work should be noted. The results are based on 3-month long trials and the results may not be extrapolated to longer treatment durations. The results of these studies also may not generalize to all individuals with chronic pain conditions, since patients with certain comorbidities were excluded from the studies.</p><p>Based on the study design for each of the individual studies, the time-to-onset of significant pain relief may not be comparable. However, in a majority of the studies, the time-to-onset of response is 1 to 2 weeks.</p><p>Even though IMMPACT recommends assessing mental functioning as part of the clinical response using Beck Depression Inventory (BDI) in clinical trials, this paper did not include such analyses because BDI was only collected in 8 of the 12 studies. These studies excluded patients with clinically significant impairment in mental function, and, in addition, patients with major depressive disorder (MDD) were excluded from all studies except those in FM. As a result, the BDI total scores at baseline were very low (ranges from 4.29 to 7.33 for studies that excluded MDD) at the outset and consequently there was not much room for improvement.</p><p>In summary, the analyses reported here show that duloxetine is efficacious in treating four distinctively different chronic pain conditions, as demonstrated by clinically significant improvement in pain severity, physical functioning, and patients&#x02019; ratings of overall improvement. The overall pattern and magnitude of response were comparable across the 4 chronic pain conditions, suggesting that duloxetine is an effective centrally-acting general analgesic.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>This work was sponsored by Eli Lilly and Company and Boehringer Ingelheim GmbH.</p></ack><sec><title>CONFLICTS OF INTEREST STATEMENT</title><p>Drs. Skljarevski, Iyengar, D&#x02019;Souza, Chappell, and Wernicke, Ms. Zhang and Ms. Alaka are employees and stockholders of Eli Lilly and Company.</p><p>Duloxetine is marketed by Eli Lilly and Company under the brand name Cymbalta<sup>&#x000ae;</sup>.</p></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Harstall</surname><given-names>C</given-names></name><name><surname>Ospina</surname><given-names>M</given-names></name></person-group><article-title>How prevalent is chronic pain?</article-title><source>Pain: Clinical Updates</source><year>2003</year><volume>Vol IX</volume><issue>2</issue></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Breivik</surname><given-names>H</given-names></name><name><surname>Collett</surname><given-names>B</given-names></name><name><surname>Ventafridda</surname><given-names>V</given-names></name><name><surname>Cohen</surname><given-names>R</given-names></name><name><surname>Gallacher</surname><given-names>D</given-names></name></person-group><article-title>Survey
of chronic pain in Europe: prevalence, impact on daily life, and
treatment</article-title><source>Eur J Pain</source><year>2006</year><volume>10</volume><issue>4</issue><fpage>287</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">16095934</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Toblin</surname><given-names>RL</given-names></name><name><surname>Mack</surname><given-names>KA</given-names></name><name><surname>Perveen</surname><given-names>G</given-names></name><name><surname>Paulozzi</surname><given-names>LJ</given-names></name></person-group><article-title>A population-based
survey of chronic pain and its treatment with prescription drugs</article-title><source>
Pain</source><year>2011</year><volume>152</volume><issue>6</issue><fpage>1249</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">21397401</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="other" publisher-type="web"><collab>American Pain Foundation</collab><article-title>Based on National Pain Survey,
Conducted for Ortho-McNeil Pharmaceutical</article-title><source><uri xlink:type="simple" xlink:href="http://www.painfoundation.org/newsroom/reporter-resources/pain-facts-figures.html">http://www.painfoundation.org/newsroom/reporter-resources/pain-facts-figures.html</uri></source><date-in-citation content-type="access-date">Accessed 28 October, 2010</date-in-citation></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Carr</surname><given-names>DB</given-names></name><name><surname>Goudas</surname><given-names>LC</given-names></name></person-group><article-title>Acute pain</article-title><source>Lancet</source><year>1999</year><volume>353</volume><issue>9169</issue><fpage>2051</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10376632</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal" publisher-type="journal"><collab>American Academy of Pediatrics</collab><article-title>Committee on Psychosocial
Aspects of Child and Family Health; Task Force on Pain in Infants,
Children, and Adolescents. The assessment and management of
acute pain in infants, children, and adolescents</article-title><source>Pediatrics</source><year>2001</year><volume>108</volume><fpage>793</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11533354</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> McCarberg</surname><given-names>B</given-names></name></person-group><article-title>Contemporary management of chronic pain
disorders</article-title><source>J Fam Pract</source><year>2004</year><volume>53</volume><issue>10 Suppl</issue><fpage>S11</fpage><lpage>S22</lpage><pub-id pub-id-type="pmid">15469761</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="book" publisher-type="book"><person-group person-group-type="author"><name><surname> Galer</surname><given-names>BS</given-names></name><name><surname>Dworkin</surname><given-names>RH</given-names></name></person-group><source>A clinical guide to neuropathic pain</source><year>2000</year><publisher-loc>McGraw-Hill</publisher-loc><publisher-name>Philadelphia</publisher-name></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Campbell</surname><given-names>JN</given-names></name><name><surname>Meyer</surname><given-names>RA</given-names></name></person-group><article-title>Mechanisms of neuropathic pain</article-title><source>Neuron
</source><year>2006</year><volume>52</volume><fpage>77</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17015228</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Tracey</surname><given-names>I</given-names></name><name><surname>Mantyh</surname><given-names>PW</given-names></name></person-group><article-title>The cerebral signature for pain perception
and its modulation</article-title><source>Neuron</source><year>2007</year><volume>55</volume><fpage>377</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">17678852</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Apkarian</surname><given-names>AV</given-names></name><name><surname>Baliki</surname><given-names>MN</given-names></name><name><surname>Geha</surname><given-names>PY</given-names></name></person-group><article-title>Towards a theory of chronic
pain</article-title><source>Prog Neurobiol</source><year>2009</year><volume>87</volume><fpage>81</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">18952143</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Ren</surname><given-names>K</given-names></name><name><surname>Dubner</surname><given-names>R</given-names></name></person-group><article-title>Neuron-glia crosstalk gets serious: role in pain
hypersensitivity</article-title><source>Curr Opin Anaesthesiol</source><year>2008</year><volume>21</volume><fpage>570</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18784481</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Woolf</surname><given-names>CJ</given-names></name></person-group><article-title>Pain: moving from symptom control toward mechanism-specific
pharmacologic management</article-title><source>Ann Intern Med</source><year>2004</year><volume>140</volume><fpage>441</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15023710</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Basbaum</surname><given-names>AI</given-names></name><name><surname>Fields</surname><given-names>HL</given-names></name></person-group><article-title>Endogenous pain control systems:
brainstem spinal pathways and endorphin circuitry</article-title><source>Annu Rev
Neurosci</source><year>1984</year><volume>7</volume><fpage>309</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">6143527</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Suzuki</surname><given-names>R</given-names></name><name><surname>Rygh</surname><given-names>LJ</given-names></name><name><surname>Dickenson</surname><given-names>AH</given-names></name></person-group><article-title>Bad news from the brain:
descending 5-HT pathways that control spinal pain processing</article-title><source>
Trends Pharmacol Sci</source><year>2004</year><volume>25</volume><fpage>613</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15530638</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Bannister</surname><given-names>K</given-names></name><name><surname>Bee</surname><given-names>LA</given-names></name><name><surname>Dickenson</surname><given-names>AH</given-names></name></person-group><article-title>Preclinical and early clinical
investigations related to monoaminergic pain modulation</article-title><source>
Neurotherapeutics</source><year>2009</year><volume>6</volume><issue>4</issue><fpage>703</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19789074</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Bellingham</surname><given-names>GA</given-names></name><name><surname>Peng</surname><given-names>PW</given-names></name></person-group><article-title>Duloxetine: A review of its
pharmacology and use in chronic pain management</article-title><source>Reg Anesth
Pain Med</source><year>2010</year><volume>5</volume><fpage>294</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">20921842</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Bymaster</surname><given-names>FP</given-names></name><name><surname>Lee</surname><given-names>TC</given-names></name><name><surname>Knadler</surname><given-names>MP</given-names></name><name><surname>Detke</surname><given-names>MJ</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name></person-group><article-title>The dual
transporter inhibitor duloxetine: a review of its preclinical
pharmacology, pharmacokinetic profile, and clinical results in
depression</article-title><source>Curr Pharm Des</source><year>2005</year><volume>11</volume><fpage>1475</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15892657</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Iyengar</surname><given-names>S</given-names></name><name><surname>Webster</surname><given-names>AA</given-names></name><name><surname>Hemrick-Luecke</surname><given-names>SK</given-names></name><name><surname>Xu</surname><given-names>JY</given-names></name><name><surname>Simmons</surname><given-names>
RM</given-names></name></person-group><article-title>Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine
reuptake inhibitor in persistent pain models in rats</article-title><source>
J Pharmacol Exp Ther</source><year>2004</year><volume>311</volume><fpage>576</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">15254142</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Jones</surname><given-names>CK</given-names></name><name><surname>Peters</surname><given-names>SC</given-names></name><name><surname>Shannon</surname><given-names>HE</given-names></name></person-group><article-title>Efficacy of duloxetine, a potent
and balanced serotonergic and noradrenergic reuptake inhibitor, in
inflammatory and acute pain models in rodents</article-title><source>J Pharmacol Exp
Ther</source><year>2005</year><volume>312</volume><fpage>726</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15494550</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Jones</surname><given-names>CK</given-names></name><name><surname>Peters</surname><given-names>SC</given-names></name><name><surname>Shannon</surname><given-names>HE</given-names></name></person-group><article-title>Synergistic interactions
between the dual serotonergic, noradrenergic reuptake inhibitor
duloxetine and the non-steroidal anti-inflammatory drug ibuprofen
in inflammatory pain in rodents</article-title><source>Eur J Pain</source><year>2007</year><volume>11</volume><fpage>208</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">16542861</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Goldstein</surname><given-names>DJ</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Detke</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>TC</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name></person-group><article-title>Duloxetine vs.
placebo in patients with painful diabetic neuropathy</article-title><source>Pain</source><year>2005</year><volume>
116</volume><fpage>109</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">15927394</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Raskin</surname><given-names>J</given-names></name><name><surname>Pritchett</surname><given-names>YL</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>A double-blind, randomized
multicenter trial comparing duloxetine with placebo in the
management of diabetic peripheral neuropathic pain</article-title><source>Pain Med
</source><year>2005</year><volume>6</volume><fpage>346</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">16266355</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wernicke</surname><given-names>JF</given-names></name><name><surname>Pritchett</surname><given-names>YL</given-names></name><name><surname>D'Souza</surname><given-names>DN</given-names></name><etal/></person-group><article-title>A randomized
controlled trial of duloxetine in diabetic peripheral neuropathic
pain</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>1411</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">17060567</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Arnold</surname><given-names>LM</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Crofford</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>A double-blind, multicenter
trial comparing duloxetine with placebo in the treatment of
fibromyalgia patients with or without major depressive disorder</article-title><source>
Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>2974</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">15457467</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Arnold</surname><given-names>LM</given-names></name><name><surname>Rosen</surname><given-names>A</given-names></name><name><surname>Pritchett</surname><given-names>YL</given-names></name><etal/></person-group><article-title>A randomized, double-blind,
placebo-controlled trial of duloxetine in the treatment of
women with fibromyalgia with or without major depressive
disorder</article-title><source>Pain</source><year>2005</year><volume>119</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">16298061</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Russell</surname><given-names>IJ</given-names></name><name><surname>Mease</surname><given-names>PJ</given-names></name><name><surname>Smith</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Efficacy and safety of
duloxetine for treatment of fibromyalgia in patients with or without
major depressive disorder: Results from a 6-month, randomized,
double-blind, placebo-controlled, fixed-dose trial</article-title><source>Pain</source><year>2008</year><volume>136</volume><fpage>
432</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">18395345</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Chappell</surname><given-names>AS</given-names></name><name><surname>Bradley</surname><given-names>LA</given-names></name><name><surname>Wiltse</surname><given-names>C</given-names></name><etal/></person-group><article-title>A six-month double-blind,
placebo-controlled, randomized clinical trial of duloxetine
for the treatment of fibromyalgia</article-title><source>Int J Gen Med</source><year>2009</year><volume>30</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">20428412</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Chappell</surname><given-names>AS</given-names></name><name><surname>Desaiah</surname><given-names>D</given-names></name><name><surname>Liu-Seifert</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Skljarevski</surname><given-names>V</given-names></name><name><surname>
Belenkov</surname><given-names>Y</given-names></name><name><surname>Brown</surname><given-names>JP</given-names></name></person-group><article-title>A double-blind, randomized, placebo-controlled
study of the efficacy and safety of duloxetine for the
treatment of chronic pain due to osteoarthritis of the knee</article-title><source>Pain
Pract</source><year>2011</year><volume>11</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">20602715</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Chappell</surname><given-names>AS</given-names></name><name><surname>Ossanna</surname><given-names>MJ</given-names></name><name><surname>Liu-Seifert</surname><given-names>J</given-names></name><etal/></person-group><article-title>Duloxetine, a
centrally acting analgesic, in the treatment of patients with
osteoarthritis knee pain: A 13-week, randomized, placebo-controlled
trial</article-title><source>Pain</source><year>2009</year><volume>146</volume><fpage>253</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19625125</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Skljarevski</surname><given-names>V</given-names></name><name><surname>Ossanna</surname><given-names>M</given-names></name><name><surname>Liu-Seifert</surname><given-names>H</given-names></name><etal/></person-group><article-title>A double-blind,
randomized trial of duloxetine versus placebo in the management
of chronic low back pain</article-title><source>Eur J Neurol</source><year>2009</year><volume>16</volume><fpage>1041</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19469829</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="other" publisher-type="journal"><person-group person-group-type="author"><name><surname> Skljarevski</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Desaiah</surname><given-names>D</given-names></name><etal/></person-group><article-title>Duloxetine versus
placebo in patients with chronic low back pain: a 12-week, fixed-dose,
randomized, double-blind trial</article-title><source>J Pain</source><comment>in press</comment><year>2010</year></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Dworkin</surname><given-names>RH</given-names></name><name><surname>Turk</surname><given-names>DC</given-names></name><name><surname>Wyrwich</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Interpreting the
clinical importance of treatment outcomes in chronic pain clinical
trials: IMMPACT recommendations</article-title><source>J Pain</source><year>2008</year><volume>9</volume><fpage>105</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">18055266</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wernicke</surname><given-names>JF</given-names></name><name><surname>Gahimer</surname><given-names>J</given-names></name><name><surname>Yalcin</surname><given-names>I</given-names></name><name><surname>Wulster-Radcliffe</surname><given-names>M</given-names></name><name><surname>Viktrup</surname><given-names>L</given-names></name></person-group><article-title>
Safety and adverse event profile of duloxetine</article-title><source>Expert Opin Drug
Saf</source><year>2005</year><volume>4</volume><fpage>987</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16255658</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wernicke</surname><given-names>J</given-names></name><name><surname>Lled&#x000f3;</surname><given-names>A</given-names></name><name><surname>Raskin</surname><given-names>J</given-names></name><name><surname>Kajdasz</surname><given-names>DK</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>An
evaluation of the cardiovascular safety profile of duloxetine:
findings from 42 placebo-controlled studies</article-title><source>Drug Saf</source><year>2007</year><volume>30</volume><fpage>
437</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">17472422</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wernicke</surname><given-names>J</given-names></name><name><surname>Acharya</surname><given-names>N</given-names></name><name><surname>Strombom</surname><given-names>I</given-names></name><etal/></person-group><article-title>Hepatic effects of
duloxetine - II: spontaneous reports and epidemiology of hepatic
events</article-title><source>Curr Drug Saf</source><year>2008</year><volume>3</volume><fpage>143</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18690992</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wernicke</surname><given-names>J</given-names></name><name><surname>Pangallo</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Hepatic effects of
duloxetine - I: non-clinical and clinical trial data</article-title><source>Curr Drug Saf
</source><year>2008</year><volume>3</volume><fpage>132</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">18690991</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wernicke</surname><given-names>JF</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Kajdasz</surname><given-names>DK</given-names></name><name><surname>Houston</surname><given-names>J</given-names></name></person-group><article-title>Safety and
tolerability of duloxetine treatment of diabetic peripheral
neuropathic pain between patients with and without cardiovascular
conditions</article-title><source>J Diabetic Complications</source><year>2009</year><volume>23</volume><fpage>349</fpage><lpage>59</lpage></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wohlreich</surname><given-names>MM</given-names></name><name><surname>Acharya</surname><given-names>N</given-names></name><name><surname>Strombom</surname><given-names>I</given-names></name><etal/></person-group><article-title>Answers to the
most common questions about the hepatic safety profile of
duloxetine</article-title><source>Postgrad Med</source><year>2008</year><volume>120</volume><fpage>111</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18654076</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Strombom</surname><given-names>I</given-names></name><name><surname>Wernicke</surname><given-names>JF</given-names></name><name><surname>Seeger</surname><given-names>J</given-names></name><name><surname>D'Souza</surname><given-names>DN</given-names></name><name><surname>Acharya</surname><given-names>N</given-names></name></person-group><article-title>
Hepatic effects of duloxetine &#x02013; III: analysis of hepatic events using
external data sources</article-title><source>Curr Drug Saf</source><year>2008</year><volume>3</volume><fpage>154</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">18690993</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Gahimer</surname><given-names>J</given-names></name><name><surname>Wernicke</surname><given-names>J</given-names></name><name><surname>Yalcin</surname><given-names>I</given-names></name><name><surname>Ossanna</surname><given-names>MJ</given-names></name><name><surname>Wulster-Radcliffe</surname><given-names>
M</given-names></name><name><surname>Viktrup</surname><given-names>L</given-names></name></person-group><article-title>A retrospective pooled analysis of duloxetine safety
in 23,983 subjects</article-title><source>Curr Med Res Opin</source><year>2007</year><volume>23</volume><fpage>175</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">17257478</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Wasan</surname><given-names>AD</given-names></name><name><surname>Ossanna</surname><given-names>MJ</given-names></name><name><surname>Raskin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety and efficacy of
duloxetine in the treatment of diabetic peripheral neuropathic pain
in older patients</article-title><source>Curr Drug Saf</source><year>2009</year><volume>4</volume><fpage>22</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19149522</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Skljarevski</surname><given-names>V</given-names></name><name><surname>Desaiah</surname><given-names>D</given-names></name><name><surname>Liu-Seifert</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy and safety
of duloxetine in patients with chronic low back pain</article-title><source>Spine</source><year>2010</year><volume>
35</volume><fpage>578</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">20118843</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Bellamy</surname><given-names>N</given-names></name><name><surname>Buchanan</surname><given-names>WW</given-names></name><name><surname>Goldsmith</surname><given-names>CH</given-names></name><name><surname>Campbell</surname><given-names>J</given-names></name><name><surname>Stitt</surname><given-names>LW</given-names></name></person-group><article-title>
Validation study of WOMAC: a health status instrument for
measuring clinically important patient relevant outcomes to
antirheumatic drug therapy in patients with osteoarthritis of the hip
or knee</article-title><source>J Rheumatol</source><year>1988</year><volume>15</volume><fpage>1833</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">3068365</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Roland</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>R</given-names></name></person-group><article-title>A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability
in low-back pain</article-title><source>Spine</source><year>1983</year><volume>8</volume><fpage>141</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">6222486</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Tubach</surname><given-names>F</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><name><surname>Baron</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evaluation of clinically
relevant changes in patient reported outcomes in knee and hip
osteoarthritis: the minimal clinically important improvement</article-title><source>Ann
Rheum Dis</source><year>2005</year><volume>64</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15208174</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Bombardier</surname><given-names>C</given-names></name><name><surname>Hayden</surname><given-names>J</given-names></name><name><surname>Beaton</surname><given-names>DE</given-names></name></person-group><article-title>Minimal clinically important
difference. Low back pain: outcome measures</article-title><source>J Rheumatol</source><year>2001</year><volume>
28</volume><fpage>431</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11246692</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Ostelo</surname><given-names>RW</given-names></name><name><surname>de Vet</surname><given-names>HC</given-names></name></person-group><article-title>Clinically important outcomes in low back
pain</article-title><source>Best Pract Res Clin Rheumatol</source><year>2005</year><volume>19</volume><fpage>593</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">15949778</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Ostelo</surname><given-names>RW</given-names></name><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Stratford</surname><given-names>P</given-names></name><etal/></person-group><article-title>Interpreting change scores
for pain and functional status in low back pain: towards
international consensus regarding minimal important change</article-title><source>Spine
</source><year>2008</year><volume>33</volume><fpage>90</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">18165753</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Costigan</surname><given-names>M</given-names></name><name><surname>Scholz</surname><given-names>J</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><article-title>Neuropathic pain: a maladaptive
response of the nervous system to damage</article-title><source>Annu Rev Neurosci
</source><year>2009</year><volume>32</volume><fpage>1</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">19400724</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Hochman</surname><given-names>JR</given-names></name><name><surname>French</surname><given-names>MR</given-names></name><name><surname>Bermingham</surname><given-names>SL</given-names></name><name><surname>Hawker</surname><given-names>GA</given-names></name></person-group><article-title>The
nerve of osteoarthritis pain</article-title><source>Arthritis Care Res (Hoboken)</source><year>2010</year><volume>
62</volume><issue>7</issue><fpage>1019</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">20589688</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Vera-Portocarrero</surname><given-names>LP</given-names></name><name><surname>Zhang</surname><given-names>ET</given-names></name><name><surname>Ossipov</surname><given-names>MH</given-names></name><name><surname>Xie</surname><given-names>JY</given-names></name><name><surname>King</surname><given-names>T</given-names></name><name><surname>
Lai</surname><given-names>J</given-names></name><name><surname>Porreca</surname><given-names>F</given-names></name></person-group><article-title>Descending facilitation from the rostral
ventromedial medulla maintains nerve injury-induced central
sensitization</article-title><source>Neuroscience</source><year>2006</year><volume>140</volume><issue>4</issue><fpage>1311</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16650614</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Farrar</surname><given-names>JT</given-names></name><name><surname>Young</surname><given-names>JP</given-names></name><name><surname>LaMoreaux</surname><given-names>L</given-names></name><name><surname>Werth</surname><given-names>JL</given-names></name><name><surname>Poole</surname><given-names>RM</given-names></name></person-group><article-title>Clinical
importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale</article-title><source>Pain</source><year>2001</year><volume>94</volume><fpage>149</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">11690728</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Robinson</surname><given-names>ME</given-names></name><name><surname>Brown</surname><given-names>JL</given-names></name><name><surname>George</surname><given-names>SZ</given-names></name><etal/></person-group><article-title>Multidimensional
success criteria and expectations for treatment of chronic pain: the
patient perspective</article-title><source>Pain Med</source><year>2005</year><volume>6</volume><fpage>336</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">16266354</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname> Farrar</surname><given-names>JT</given-names></name><name><surname>Pritchett</surname><given-names>YL</given-names></name><name><surname>Robinson</surname><given-names>M</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Chappell</surname><given-names>A</given-names></name></person-group><article-title>The
clinical importance of changes in the 0 to 10 numeric rating scale
for worst, least, and average pain intensity: analyses of data from
clinical trials of duloxetine in pain disorders</article-title><source>J Pain</source><year>2010</year><volume>11</volume><fpage>109</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">19665938</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Summary of 24-Hour Average Pain Rating (3-Month Results) Across All Chronic Pain Studies of Duloxetine</p></caption><table frame="border" rules="cols" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Indication</th><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="left" rowspan="1" colspan="1">Mean Change (SE)</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></thead><tbody><tr><td rowspan="5" valign="top" colspan="1">
OA</td><td rowspan="2" valign="top" colspan="1">
HMFG</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.72 (0.18)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">-2.51 (0.20)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">
HMEP</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.93 (0.18)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">-2.64 (0.19)<xref ref-type="table-fn" rid="T1F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="9" valign="top" colspan="1">
CLBP</td><td rowspan="2" valign="top" colspan="1">
HMEN</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.45 (0.21)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">-2.09 (0.21)<xref ref-type="table-fn" rid="T1F2">*</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">
HMEO</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.82 (0.20)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-2.27 (0.20)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 120 mg</td><td rowspan="1" colspan="1">-2.21 (0.20)</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">
HMGC</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.65 (0.15)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-2.25 (0.15)<xref ref-type="table-fn" rid="T1F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="11" valign="top" colspan="1">
DPNP</td><td rowspan="3" valign="top" colspan="1">
HMAW</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.69 (0.24)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-2.86 (0.24)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine 120 mg</td><td rowspan="1" colspan="1">-3.14 (0.24)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">
HMAVa</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.39 (0.23)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-2.72 (0.22)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine 120 mg</td><td rowspan="1" colspan="1">-2.84 (0.23)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">
HMAVb</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.60 (0.18)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-2.50 (0.18)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine 120 mg</td><td rowspan="1" colspan="1">-2.47 (0.18)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="13" valign="top" colspan="1">
Fibromyalgia</td><td rowspan="2" valign="top" colspan="1">
HMBO</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-0.67 (0.22)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 120 mg</td><td rowspan="1" colspan="1">-1.43 (0.22)<xref ref-type="table-fn" rid="T1F2">*</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">
HMCA</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.16 (0.21)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-2.39 (0.22)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine 120 mg</td><td rowspan="1" colspan="1">-2.40 (0.22)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">
HMCJ</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.39 (0.20)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-1.99 (0.20)<xref ref-type="table-fn" rid="T1F2">*</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine 120 mg</td><td rowspan="1" colspan="1">-2.31 (0.20)<xref ref-type="table-fn" rid="T1F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">
HMEF</td><td rowspan="1" colspan="1">
Placebo</td><td rowspan="1" colspan="1">
-1.17 (0.19)</td></tr><tr><td rowspan="1" colspan="1">Duloxetine 60 mg</td><td rowspan="1" colspan="1">-1.50 (0.20)</td></tr></tbody></table><table-wrap-foot><fn id="T1F1"><p>Abbreviations: OA-osteoarthritis, CLBP-chronic low back pain, DPNP-diabetic peripheral neuropathic pain, SE-standard error.</p></fn><fn id="T1F2"><label>*</label><p>P&#x0003c;.05 versus placebo,</p></fn><fn id="T1F3"><label>**</label><p>P&#x0003c;.01 versus placebo,</p></fn><fn id="T1F4"><label>***</label><p>P&#x0003c;.001 versus placebo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Summary of 30% and 50%Average Pain Rating (3-Month Results) Across All Chronic Pain Studies of Duloxetine</p></caption><table frame="border" rules="cols" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">
Indication</th><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="left" rowspan="1" colspan="1">30%Response Rate, (%)</th><th align="left" rowspan="1" colspan="1">50%Response Rate, (%)</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr></thead><tbody><tr><td rowspan="5" valign="top" colspan="1">OA</td><td rowspan="2" valign="top" colspan="1">HMFG</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">44.1</td><td rowspan="1" colspan="1">32.3</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">65.3<xref ref-type="table-fn" rid="T2F4">***</xref></td><td rowspan="1" colspan="1">43.8</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMEP</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">44.5</td><td rowspan="1" colspan="1">29.4</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">59.3<xref ref-type="table-fn" rid="T2F2">*</xref></td><td rowspan="1" colspan="1">47.2<xref ref-type="table-fn" rid="T2F3">**</xref></td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="9" valign="top" colspan="1">CLBP</td><td rowspan="2" valign="top" colspan="1">HMEN</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">40.0</td><td rowspan="1" colspan="1">27.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">53.2</td><td rowspan="1" colspan="1">38.5</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMEO</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">43.4</td><td rowspan="1" colspan="1">29.2</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">53.6</td><td rowspan="1" colspan="1">34.5</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">57.8<xref ref-type="table-fn" rid="T2F2">*</xref></td><td rowspan="1" colspan="1">36.7</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMGC</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">48.7</td><td rowspan="1" colspan="1">34.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">56.9</td><td rowspan="1" colspan="1">48.7<xref ref-type="table-fn" rid="T2F3">**</xref></td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="11" valign="top" colspan="1">DPNP</td><td rowspan="3" valign="top" colspan="1">HMAW</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">33.0</td><td rowspan="1" colspan="1">26.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">56.0<xref ref-type="table-fn" rid="T2F4">***</xref></td><td rowspan="1" colspan="1">49.0<xref ref-type="table-fn" rid="T2F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">56.0<xref ref-type="table-fn" rid="T2F4">***</xref></td><td rowspan="1" colspan="1">52.0<xref ref-type="table-fn" rid="T2F4">***</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMAVa</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">41.5</td><td rowspan="1" colspan="1">27.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">62.7<xref ref-type="table-fn" rid="T2F3">**</xref></td><td rowspan="1" colspan="1">43.0<xref ref-type="table-fn" rid="T2F2">*</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">69.4<xref ref-type="table-fn" rid="T2F4">***</xref></td><td rowspan="1" colspan="1">53.0<xref ref-type="table-fn" rid="T2F4">***</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMAVb</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">43.4</td><td rowspan="1" colspan="1">30.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">68.1<xref ref-type="table-fn" rid="T2F4">***</xref></td><td rowspan="1" colspan="1">50.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">64.0<xref ref-type="table-fn" rid="T2F3">**</xref></td><td rowspan="1" colspan="1">39.0</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="13" valign="top" colspan="1">Fibromyalgia</td><td rowspan="2" valign="top" colspan="1">HMBO</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">26.5</td><td rowspan="1" colspan="1">14.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">38.0</td><td rowspan="1" colspan="1">26.0<xref ref-type="table-fn" rid="T2F2">*</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMCA</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">33.0x</td><td rowspan="1" colspan="1">23.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">55.0<xref ref-type="table-fn" rid="T2F4">***</xref></td><td rowspan="1" colspan="1">41.0<xref ref-type="table-fn" rid="T2F3">**</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">41.0<xref ref-type="table-fn" rid="T2F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMCJ</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">36.0</td><td rowspan="1" colspan="1">23.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">50.7<xref ref-type="table-fn" rid="T2F2">*</xref></td><td rowspan="1" colspan="1">34.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">52.1<xref ref-type="table-fn" rid="T2F3">**</xref></td><td rowspan="1" colspan="1">40.1<xref ref-type="table-fn" rid="T2F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMEF</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">31.7</td><td rowspan="1" colspan="1">25.1</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">37.3</td><td rowspan="1" colspan="1">29.1</td></tr></tbody></table><table-wrap-foot><fn id="T2F1"><p>Abbreviations: OA-osteoarthritis, CLBP-chronic low back pain, DPNP-diabetic peripheral neuropathic pain, %-percent.</p></fn><fn id="T2F2"><label>*</label><p>P&#x0003c;.05 versus placebo,</p></fn><fn id="T2F3"><label>**</label><p>P&#x0003c;.01 versus placebo,</p></fn><fn id="T2F4"><label>***</label><p>P&#x0003c;.001 versus placebo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Summary of Physical Function Response Rate Analysis (3-Month Results) Across All Chronic Pain Studies of Duloxetine</p></caption><table frame="border" rules="cols" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">
Indication</th><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="left" rowspan="1" colspan="1">%</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></thead><tbody><tr><td rowspan="5" valign="top" colspan="1">OA: Response
rate based on WOMAC score</td><td rowspan="2" valign="top" colspan="1">HMFG</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">55.9</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">72.4<xref ref-type="table-fn" rid="T3F2">*</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMEP</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">40.9</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">71.3<xref ref-type="table-fn" rid="T3F4">***</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="9" valign="top" colspan="1">CLBP:
Response rate based on RMDQ
score (Change &#x02264;-3.5)</td><td rowspan="2" valign="top" colspan="1">HMEN</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">28.6</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">40.4</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMEO</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">38.6</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">39.8</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMGC</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">33.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">41.6</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="11" valign="top" colspan="1">DPNP:
Response rate based on BPI average physical interference (average of
physical interference items: general activity, walking ability &#x00026; normal
work)</td><td rowspan="3" valign="top" colspan="1">HMAW</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">59.8</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">68.1</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">72.5</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMAVa</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">61.5</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">68.5</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">78.5<xref ref-type="table-fn" rid="T3F3">**</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMAVb</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">56.9</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">68.5</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">76.9<xref ref-type="table-fn" rid="T3F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="13" valign="top" colspan="1">
Fibromyalgia: Response rate based on BPI average physical interference
(average of physical interference items: general activity, walking
ability &#x00026; normal work</td><td rowspan="2" valign="top" colspan="1">HMBO</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">38.2</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">57.4<xref ref-type="table-fn" rid="T3F3">**</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMCA</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">51.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">71.6<xref ref-type="table-fn" rid="T3F3">**</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">65.8<xref ref-type="table-fn" rid="T3F2">*</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMCJ</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">54.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">66.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">73.9<xref ref-type="table-fn" rid="T3F4">***</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMEF</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">46.1</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">58.9<xref ref-type="table-fn" rid="T3F2">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T3F1"><p>Abbreviations: OA-osteoarthritis, CLBP-chronic low back pain, DPNP-diabetic peripheral neuropathic pain, %-percent, WOMAC- Western Ontario and McMaster Universities,
RMDQ- Roland Morris Disability Questionnaire, BPI-Brief Pain Inventory.</p></fn><fn id="T3F2"><label>*</label><p>P&#x0003c;.05 versus placebo,</p></fn><fn id="T3F3"><label>**</label><p>P&#x0003c;.01 versus placebo,</p></fn><fn id="T3F4"><label>***</label><p>P&#x0003c;.001 versus placebo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Summary of PGI-Improvement Response Rate Analysis (3-Month Results) Across All Chronic Pain Studies of Duloxetine</p></caption><table frame="border" rules="cols" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">
Indication</th><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="left" rowspan="1" colspan="1">%</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></thead><tbody><tr><td rowspan="5" valign="top" colspan="1">OA</td><td rowspan="2" valign="top" colspan="1">HMFG</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">29.1</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">42.3<xref ref-type="table-fn" rid="T4F2">*</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMEP</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">40.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">61.3<xref ref-type="table-fn" rid="T4F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="9" valign="top" colspan="1">CLBP</td><td rowspan="2" valign="top" colspan="1">HMEN</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 &#x02013; 120 mg</td><td rowspan="1" colspan="1">45.9<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMEO</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">38.6</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">55.6<xref ref-type="table-fn" rid="T4F2">*</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">52.3<xref ref-type="table-fn" rid="T4F2">*</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMGC</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">32.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">46.4<xref ref-type="table-fn" rid="T4F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="11" valign="top" colspan="1">DPNP</td><td rowspan="3" valign="top" colspan="1">HMAW</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">31.5</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">57.7<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">58.7<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMAVa</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">32.4</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">58.0<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">63.6<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMAVb</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">29.5</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">52.3<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">48.6<xref ref-type="table-fn" rid="T4F3">**</xref></td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td rowspan="13" valign="top" colspan="1">Fibromyalgia</td><td rowspan="2" valign="top" colspan="1">HMBO</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">25.3</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">36.8</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMCA</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">21.6</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">43.0<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">45.9<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" colspan="1">HMCJ</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">23.7</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">35.7<xref ref-type="table-fn" rid="T4F2">*</xref></td></tr><tr><td rowspan="1" colspan="1">Duloxetine
120 mg</td><td rowspan="1" colspan="1">43.7<xref ref-type="table-fn" rid="T4F4">***</xref></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" colspan="1">HMEF</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">18.0</td></tr><tr><td rowspan="1" colspan="1">Duloxetine
60 mg</td><td rowspan="1" colspan="1">28.3<xref ref-type="table-fn" rid="T4F2">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T4F1"><p>Abbreviations: OA-osteoarthritis, CLBP-chronic low back pain, DPNP-diabetic peripheral neuropathic pain, %-percent.</p></fn><fn id="T4F2"><label>*</label><p>P&#x0003c;.05 versus placebo,</p></fn><fn id="T4F3"><label>**</label><p>P&#x0003c;.01 versus placebo,</p></fn><fn id="T4F4"><label>***</label><p>P&#x0003c;.001 versus placebo.</p></fn></table-wrap-foot></table-wrap></floats-group></article>